Drug Trial Radar · NCT04347005
The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males
Last checked: Nov 19, 2026Latest source record: Nov 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jan 22, 2019
Primary completion
Jul 31, 2019
Study completion Jul 31, 2019
Sponsor
- Lead sponsor
- Arthrosi TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.
Conditions
- Healthy Volunteers
Interventions
Cohort 1: AR882Drug
Single dose of AR882 or matching placebo
Cohort 2: AR882Drug
Single dose of AR882 or matching placebo
Cohort 3: AR882Drug
Single dose of AR882 or matching placebo
Cohort 4: AR882Drug
Single dose of AR882 or matching placebo
Cohort 5: AR882Drug
Single dose of AR882 or matching placebo
Cohort 6: AR882 Food EffectDrug
Single dose of AR882 or matching placebo in a fed state
Cohort 7: AR882 Solid Oral FormulationDrug
Single dose of AR882 or matching placebo
Cohort 8: AR882 in combination with allopurinolDrug
Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
Cohort 9: AR882 in combination with febuxostatDrug
Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findingsTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Safety AnalysesTime frame: 8 Days
- Area under the curve (AUC) for plasma AR882Time frame: 6 Days
- Time to maximum plasma concentration (Tmax) for AR882Time frame: 6 Days
- Maximum plasma concentration (Cmax) for AR882Time frame: 6 Days
- Apparent terminal half-life (t1/2) for AR882Time frame: 6 Days
- Amount excreted (Ae) into urine for AR882Time frame: 6 Days
- Fractional Excretion (FEUA) for AR882Time frame: 6 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty, Ltd.
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.